Antibody Innovative Drugs
Provide self-developed sequence editing and design tools and a unified data foundation, deeply integrating the DeepSeek LLM with a self-developed knowledge graph. Covering every step from sequence design, clone construction, expression and purification, activity analysis, to process development, we help you accelerate the creation of next-generation "super antibodies".
From design to quality, keep antibody R&D measurable and reproducible.
Challenge: Antibody humanization and affinity maturation design rely heavily on empirical experience; screening data (hybridoma/phage display) is large and complex, and candidate molecules lack systematic management.
Challenge: Records of processes such as plasmid construction, primer design, and sequencing validation are scattered and difficult to trace back; key material information for vectors, cell lines, etc. is isolated, making traceability challenging.
Challenge: Upstream expression and downstream purification process data are mostly unstructured PDF reports; bioactivity assay data are scattered, making structure-activity relationship (SAR) analysis difficult.
Challenge: Data from antibody drug CMC studies is scattered and complex, making it difficult to monitor project progress and costs in real time; compiling IND submission documents is time-consuming and labor-intensive, creating potential compliance risks.
We understand that choosing an R&D platform is not just about selecting software tools; it is about choosing a continuously evolving, living product. More importantly, it is about selecting a strategic partner who understands your business and can support your growth for the next 10 or 20 years. To this end, we have built a unique combination of value.
We provide end-to-end platform solutions that ensure the seamless flow integration of data across every stage—from target discovery, lead optimization, and activity testing to DMPK, CMC, toxicology studies, CTD reporting, IND filing, and clinical bioanalysis. This approach allows you to completely eliminate the data silos and redundant work typically associated with managing multiple disparate systems.
We deeply integrate electronic lab notebooks, AI large models, and human scientific research knowledge graphs throughout core stages such as molecular design, experiment optimization, and report generation. Through continuous iteration and evolution, we aim to transform data into insights, elevate information into decisions, and truly unlock the intelligent potential of data.
From the very beginning, the platform is designed with embedded compliance requirements from major global regulatory agencies such as the FDA and NMPA (e.g., 21 CFR Part11、ALOCA+). This makes compliance and audit trails a natural part of the workflow, significantly reducing regulatory submission risks.
We provide professional services led by domain experts. Our implementation team not only understands the technology but also has years of in-depth experience in the field of small molecule innovative drug R&D. By leveraging best practices from over 700 clients, we help you quickly get started and plan the optimal implementation path, ensuring the platform perfectly aligns with your R&D workflows.
We maintain a dedicated Customer Success team to provide you with ongoing support following the system's launch. This team will proactively assist you in optimizing your workflows, assess your core requirements, continuously iterate on new features, and offer forward-looking recommendations to ensure you consistently maximize the return on your investment.
Every feature and scenario design is rooted in our profound understanding of this field—specifically its specialized know-how, R&D challenges, working habits, and regulatory landscape. This translates into less need for customization, a superior fit for your operations, and a solution that allows experts in small-molecule innovative drugs to directly address your specific pain points.
